Together, these findings unravel what we believe are previously unidentified relationships between CD8+ T cell tumor infiltration and patient prognosis and highlight CD8+ TEX as a critical feature of ER+ BC patient outcomes. This evidence concerns the gene TEX46 and breast cancer.